Education & Experience

Research & Publications

• Lee JH, Hwang SY, Kim YJ et al. Long-term Prognosis of Combined Hepatocellular and Cholangiocarcinoma After Curative Resection Comparison With Hepatocellular Carcinoma and Cholangiocarcinoma. J Clin Gastroenterol. 2011 Jan;45(1):69-75. (As Co-author)
• Chung GE, Hwang SY, Kim YJ et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology. 2011 Feb;258(2):627-34. (As Co-author)
• Chung GE, Hwang SY, Kim W et al. Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B. Dig Dis Sci. 2011 Jul;56(7):2130-6. (As Co-author)
• Lee JH, Hwang SY, Yoon JH et al. Simple scoring system predicting genotypic resistance during rescue therapy for Lamivudine-resistant chronic hepatitis B. J Clin Gastroenterol. 2012 Mar;46(3):243-50. (As Co-author)
• Lee MJ, Hwang SY, Kim JH et al. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea. Invest New Drugs 2021 Feb;39(1):260-268. (As Co-author)
• Liu H, Hwang SY, Lee SS et al. Oxidative Mechanisms and Cardiovascular Abnormalities of Cirrhosis and Portal Hypertension. JInt. J. Mol. Sci. 2023, 24(23), 16805. (As Co-author)
• Kim J, Hwang SY, Kim YJ et al. Inverse Propensity Score-Weighted Analysis of Entecavir and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B: A Large-Scale Multicenter Study. Cancers (Basel). 2023 May 26;15(11):2936. (As Co-author)
• Hwang SY, Yang KM et al. A case of achieving partial remission with combination of radiation therapy and Sorafenib in Child-Pugh class B patients with hepatocellular carcinoma with main portal vein invasion and lymph node metastasis. J Liver Cancer. 2014;14:120-126. (As First or Corresponding author)
• Hwang SY, Yang KM et al. A case of perforation of gastric ulcer after complete remission of huge hepatocellular carcinoma invading main portal vein with combination therapy of stereotactic body radiation therapy and sorafenib. J Liver Cancer. 2014;14:46-52. (As First or Corresponding author)
• Hwang SY, Yang KM et al. A case of hypovascular hepatocellular carcinoma invading bile duct with partial remission with combination therapy of transarterial chemoembolization and stereotactic body radiation therapy and sorafenib. J Liver Cancer. 2013;13:45-50. (As First or Corresponding author)
• Hwang SY, Yang KM et al. A case of huge hepatocellular carcinoma with complete remission of intrahepatic tumor and adrenal gland metastasis treated with combination therapy of transarterial chemoembolization and radiation therapy and sorafenib. J Liver Cancer. 2013;1:1-5. (As First or Corresponding author)
• Hwang SY, Song GA et al. A case of gastric metastasis of breast carcinoma resembling early gastric cancer. Korean J Gastroenterol. 2005 Dec;46(6):481-4. (As First or Corresponding author)
• Hwang SY, Jeong JB et al. A case of gastric, Duodenal and Colonic Metastases from Adenocarcinoma of the Lung. Korean J Gastrointest Endosc. 2010 Feb;40(2):102-106. (As First or Corresponding author)
• Hwang SY, Jeong JB et al. A case of cholangiocarcinoma suspected by continuous elevation of CA 19-9 after surgery of xanthogranulomatous cholecystitis. Korean J Gastroenterol. 2010 Jun;55(6):404-9. (As First or Corresponding author)
• Hwang SY, Cho M et al. Effectiveness and complications of combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis C. Korean J Gastroenterol. 2007 Mar;49(3):166-72. (As First or Corresponding author)
• Hwang SY, Roh YH et al. Extramedullary plasmacytoma of the pancreas diagnosed using endoscopic ultrasonography-guided fine needle aspiration. Clin Endosc. 2014 Jan;47(1):115-8. (As First or Corresponding author)
• Hwang SY, Yang KM et al. A case of achieving complete remission with combination of stereotactic body radiation therapy and transarterial chemoemoblization in patients with 4.8 cm sized infiltrative hepatocellular carcinoma with arteriovenous shunt. J Liver Cancer. 2015:15:64-69. (As First or Corresponding author)
• Hwang SY, Lee HW et al. Complete response in hepatocellular carcinoma with lymph node metastasis by combination therapy of atezolizumab and bevacizumab: a case report. J Liver Cancer. 2021 Sep;21(2):177-180. (As First or Corresponding author)
• Hwang SY, Jeon W et al. A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab. J Liver Cancer. 2023 Mar;23(1):213-218. (As First or Corresponding author)
• Hwang SY, Lee JH et al. Spontaneous fungal peritonitis: a severe complication in patients with advanced liver cirrhosis. Eur J Clin Microbiol Infect Dis. 2014 Feb;33(2):259-64. (As First or Corresponding author)
• Hwang SY, Yang KM et al. Emodin attenuates radioresistance induced by hypoxia in HepG2 cells via the enhancement of PARP1 cleavage and inhibition of JMJD2B. Oncol Rep. 2015 Apr;33(4):1691-8. (As First or Corresponding author)
• Hwang SY, Kim YJ et al. Reduction of oxidative stress attenuates lipoapoptosis exacerbated by hypoxia in human hepatocytes. Int J Mol Sci. 2015 Feb 3;16(2):3323-34. (As First or Corresponding author)
• Hwang SY, Kim JH et al. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study. Eur J Cancer. 2020 Nov:140:19-27.
• Hwang SY, Lee SS et al. Role of Galectin in Cardiovascular Conditions including Cirrhotic Cardiomyopathy. Pharmaceuticals (Basel). 2023 Jul 7;16(7):978 (As First or Corresponding author)
• Hwang SY, Lee SS et al. Dysregulated Calcium Handling in Cirrhotic Cardiomyopathy. Biomedicines. 2023 Jul 4;11(7):1895. (As First or Corresponding author)
• Hwang SY, Lee SS et al. Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?. Liver Cancer. 2023 Nov. https://doi.org/10.1159/000534303. (As First or Corresponding author)
• Hwang SY, Heo J et al. Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma. Cancers. 2024 16(4), 838. (As First or Corresponding author)